Built for Real Biopharma Work.
For teams working at the pace of biopharma innovation.
Find answers, draft responses, and cite every source from the documents your teams already trust.
Plain-language questions, across the content your teams already approved.
What is our position on off-label use of AVX-204 in pediatric patients?
Pediatric use is not supported for AVX-204 in patients under 18. The approved label states that safety and effectiveness have not been established in this population[1]. The standard MI response (v3.2) directs healthcare providers to the ongoing pediatric program currently in Phase 2[2].
- 1 Prescribing Information · §8.4 Pediatric Use · p. 14
- 2 MI Standard Response Library · v3.2 · §Pediatrics
Four capabilities, in one connected loop.
Ask in plain language
The way your team already asks questions. No prompt engineering, no special syntax. Just the questions they answer every day, in the language they use.
Get cited answers
Every answer is anchored to the exact passage of the exact document, with page and section references. Nothing generic, nothing hallucinated.
Dose reduction is recommended for moderate renal impairment (CrCl 30 to 59 mL/min)[1]. Severe renal impairment requires consultation with the medical team[2].
Draft responses, ready for review
First-draft responses formatted to the standards your team already uses. Your specialists review, edit, and approve before anything leaves the team.
Thank you for your inquiry regarding AVX-204. Based on the approved prescribing information, the recommended dose adjustment for patients with moderate renal impairment is a 50% reduction...
Verify the source in one click
Open the exact passage the answer came from, in context. Confirm the source before anything is sent or signed off on.
"For patients with moderate renal impairment (CrCl 30 to 59 mL/min), a 50 percent dose reduction is recommended. Monitor renal function during therapy."
Works with the systems your teams already run on.
Rightview connects to your approved content libraries, document repositories, and identity systems, without migration or replacement.
Configurable to the way your teams already operate.
Integrations
Out-of-the-box connectors for the content systems biopharma teams already run on. New connectors built on request.
Prompt library
A library of starting prompts shaped for medical, clinical, and regulatory work. Editable, extendable, and shareable across teams.
Guided implementation
A managed rollout. Not a connector you have to wire up yourself. Discovery, ingestion, calibration, and a phased go-live.
Tuned to your content
Retrieval and response behavior are calibrated to your team's documents, terminology, and writing style during implementation.
Governance & permissions
Role-based access, document-level permissions, and SSO via your identity provider. Your existing controls are preserved.
Private deployment
Single-tenant deployments available for regulated environments. Content and queries stay inside your boundary.
A managed rollout, not a connector you wire up yourself.
A four-phase implementation with a dedicated team. Most deployments see a first cohort live within sixty days.
Discovery
Map the documents your teams already work with, the recurring questions they answer, and the reviewers who sign off.
Connect & ingest
Point Rightview at your approved content libraries. Nothing migrates. Existing access controls are preserved.
Calibrate
Tune retrieval, citation format, and response style to match how your team writes today.
Roll out
First cohort live, audit logs on, reviewers trained. Iterative rollout to additional teams.
The controls regulated biopharma teams require, documented and operational.
Data handling
Customer content is never used to train models. Third-party AI providers operate under zero data retention agreements.
Source citations
Every answer is anchored to the customer's documents, with page and section references.
Audit logs
Immutable, tamper-evident logs of every query and response, retained for inspection.
21 CFR Part 11
Audit trails, electronic signatures, and role-based access controls aligned with FDA Part 11 requirements for electronic records.
Validation documentation
IQ, OQ, and PQ documentation available for regulated deployments.
AI-ready data and MCP integration
Structured, indexed retrieval surfaces, including a Model Context Protocol interface for downstream AI tooling.
Enterprise scale
API-first architecture with documented rate limits and service level agreements for enterprise deployments.
Request a demo.
A thirty-minute walkthrough of the end to end platform customized for your use case.